Novo Nordisk to Launch Ozempic in India This December as Competition Intensifies in $150 Billion Weight-Loss Market

Danish pharmaceutical giant Novo Nordisk查看公司主页 is preparing to launch its highly successful diabetes medication Ozempic查看药品详情 in India this December, according to three sources familiar with the matter. The move represents a strategic effort to strengthen the company's position in one of the world's most populous nations and a critical battleground for the rapidly expanding weight-loss treatment market.

Strategic Market Entry

The launch is expected to occur within the next three to four weeks, as Novo Nordisk查看公司主页 seeks to establish Ozempic查看药品详情's presence before generic versions enter the market. The company received Indian regulatory approval to import and sell Ozempic in September and has been working to bring the drug to market as quickly as possible.

"We understand that India is a price-sensitive market and hence we are working hard toward pricing (Ozempic查看药品详情) that is market competitive," said Vikrant Shrotriya, Managing Director of Novo Nordisk查看公司主页 India.

Massive Market Opportunity

India presents a compelling opportunity for diabetes and weight-loss treatments, ranking as the country with the second-highest number of people with type 2 diabetes after China. Combined with rising obesity rates, this positions India as a key market for pharmaceutical companies targeting the fast-growing weight-loss treatment sector, which analysts expect to reach $150 billion annually by the end of the decade.

Ozempic查看药品详情, a once-weekly injectable drug approved by the U.S. Food and Drug Administration in 2017 for type 2 diabetes management, has become a global bestseller. The medication is widely used off-label for weight loss due to its appetite-suppressing effects, belonging to a class of drugs known as GLP-1 (搜索)搜索该靶点 agonists that mimic a hormone which slows digestion and helps people feel full longer.

Competitive Landscape

The Ozempic查看药品详情 launch comes as Novo Nordisk查看公司主页 faces intensifying competition from U.S. rival Eli Lilly查看公司主页. Lilly's Mounjaro查看药品详情, approved for both diabetes and weight loss, has gained significant traction in the Indian market, becoming the country's top-selling drug by value in October according to Pharmarack data.

The competitive dynamics are evident in the sales figures: Lilly sold 262,000 doses of Mounjaro查看药品详情 in October, compared with just 26,000 doses of Novo's Wegovy查看药品详情, which entered the Indian market in June. In response to this competition, Novo cut Wegovy's price in India by up to 37% last month.

Portfolio Completion and Market Position

The launch of Ozempic查看药品详情 will complete Novo Nordisk查看公司主页's semaglutide portfolio in India, offering comprehensive treatments for both diabetes and obesity. The company already maintains a strong presence in India's diabetes market through its Rybelsus查看药品详情 semaglutide tablets and other products.

"Novo will be better poised to push Ozempic查看药品详情 because of its strong brand reputation in the diabetes therapy area," said Vishal Manchanda, an analyst at Systematix Institutional Equities. He also noted potential for expanded use, stating, "There is a possibility that Ozempic could be prescribed for those suffering with infertility, sleep apnea and looking to shed some weight."

Generic Competition on the Horizon

The urgency behind Novo's launch strategy is partly driven by the approaching patent expiration. Novo's patent on semaglutide expires in March 2026, which will open the door to cheaper generic alternatives. India's generic drugmakers, including Sun Pharma查看公司主页, Cipla查看公司主页, Dr Reddy's (搜索)搜索该词条, and Lupin查看公司主页, have been developing their own versions of semaglutide to capitalize on the weight-loss treatment opportunity.

As one source noted, "Novo wants Ozempic查看药品详情 in the market before generics bring out cheaper versions," highlighting the company's race against time to establish market share before facing generic competition in this lucrative therapeutic area.